3-iodo-N-methyl-1H-indazole-6-carboxamide | 906000-50-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 3-iodo-N-methyl-1H-indazole-6-carboxamide
• 英文别名: 3-iodo-N-methyl-1H-mdazole-6-carboxamide；3-iodo-N-methyl-2H-indazole-6-carboxamide
• CAS: 906000-50-8
• 化学式: C₉H₈IN₃O
• 分子量: 301.087
• InChiKey: QMAAAYNWKNBDLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  57.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  苯磺酰胺-3-硼酸频哪醇酯 、 3-iodo-N-methyl-1H-indazole-6-carboxamide 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 以19%的产率得到N-methyl-3-(3-sulfamoylphenyl)-1H-indazole-6-carboxamide
  参考文献：
  名称：

  Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides

  摘要：

  TTK kinase was identified by in-house siRNA screen and pursued as a tractable, novel target for cancer treatment. A screening campaign and systematic optimization, supported by computer modeling led to an indazole core with key sulfamoylphenyl and acetamido moieties at positions 3 and 5, respectively, establishing a novel chemical class culminating in identification of 72 (CFI-400936). This potent inhibitor of TTK (IC50=3.6nM) demonstrated good activity in cell based assay and selectivity against a panel of human kinases. A co-complex TTK X-ray crystal structure and results of a xenograft study with TTK inhibitors from this class are described.

  DOI：

  10.1016/j.bmc.2014.06.027
• 作为产物：
  描述：

  1H-吲唑-6-羧酸 在 碘 、 potassium carbonate 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-iodo-N-methyl-1H-indazole-6-carboxamide
  参考文献：
  名称：

  Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides

  摘要：

  TTK kinase was identified by in-house siRNA screen and pursued as a tractable, novel target for cancer treatment. A screening campaign and systematic optimization, supported by computer modeling led to an indazole core with key sulfamoylphenyl and acetamido moieties at positions 3 and 5, respectively, establishing a novel chemical class culminating in identification of 72 (CFI-400936). This potent inhibitor of TTK (IC50=3.6nM) demonstrated good activity in cell based assay and selectivity against a panel of human kinases. A co-complex TTK X-ray crystal structure and results of a xenograft study with TTK inhibitors from this class are described.

  DOI：

  10.1016/j.bmc.2014.06.027

文献信息

• Inhibitors of Checkpoint Kinases
  申请人：Arrington L. Kenneth

  公开号：US20080004259A1

  公开（公告）日：2008-01-03

  The instant invention provides for compounds which comprise substituted indolyl indazoles that inhibit CHK1 activity. The instant compounds provide a novel mechanism of action with unexpected advantageous properties; such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.

  本发明提供了一种包括取代的吲哚基吲唑化合物，能够抑制CHK1活性。这些化合物提供了一种新的作用机制，具有意想不到的优越性质；这些意想不到的优越性质可能包括增强的细胞效力/溶解度、更高的选择性、增强的药代动力学性质、缺乏非靶标活性等等。本发明还提供了包含这些抑制剂化合物的组合物以及通过向需要治疗癌症的患者投药来抑制CHK1活性的方法。
• Identification of Compounds Suitable for Treating Ad
  申请人：Churcher Ian

  公开号：US20090192155A1

  公开（公告）日：2009-07-30

  The invention provides a method of screening for compounds which inhibit the hyperphosphorylation of tau, and hence are suitable for treating AD and related conditions.

  本发明提供了一种筛选抑制tau超磷酸化的化合物的方法，因此适用于治疗AD和相关疾病。
• WO2006/86255
  申请人：——

  公开号：——

  公开（公告）日：——
• INHIBITORS OF CHECKPOINT KINASES
  申请人：Merck & Co., Inc.

  公开号：EP1851203A2

  公开（公告）日：2007-11-07
• IDENTIFICATION OF COMPOUNDS SUITABLE FOR TREATING AD
  申请人：Merck Sharp & Dohme Limited

  公开号：EP1983979A1

  公开（公告）日：2008-10-29